Immunotherapy drugs for non-small cell lung cancer include karelizumab, pembrolizumab, divalizumab and so on.
1. Carelizumab: combined with pemetrexed and carboplatin, it is suitable for the first-line treatment of EGFR-negative, ALK-negative, unresectable locally advanced or metastatic non-squamous non-small-cell lung cancer, and side effects such as malaise, anemia, and lowering of leukocytes may occur, and is forbidden to those who are allergic to it.
2. Pembrolizumab: it can be used in combination with carboplatin and paclitaxel for the first-line treatment of metastatic squamous non-small cell lung cancer, or in combination with platinum and pemetrexed for the first-line treatment of EGFR-negative, ALK-negative metastatic non-squamous non-small cell lung cancer; it may have side effects such as fatigue, rash, diarrhea, nausea, etc; and is forbidden to those who are allergic to it.
3. Duvarizumab: it is suitable for stage III unresectable non-small cell lung cancer with no disease progression after platinum-based chemotherapy and simultaneous radiotherapy, and may have side effects such as edema, fatigue, dermatitis, transaminase elevation, etc., and is prohibited for those who are allergic to it.
In addition to the above drugs, immunotherapy drugs for non-small cell lung cancer also include nabulizumab, sindilizumab and so on. Immunotherapy drugs for non-small cell lung cancer belong to antitumor therapy prescription drugs, which have their own indications and side effects, and must be applied under the guidance of specialists, not on their own.